Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer
| Autor: | N Colombo, Michael D. Green, James L. Speyer, J C Wernz, Uziel Beller, Franco M. Muggia, E M Beckman |
|---|---|
| Přispěvatelé: | Green, M, Speyer, J, Wernz, J, Colombo, N, Beller, U, Muggia, F, Beckman, E |
| Rok vydání: | 1990 |
| Předmět: |
Adult
medicine.medical_specialty Anthracycline Nausea MED/40 - GINECOLOGIA E OSTETRICIA medicine.medical_treatment Phases of clinical research Neutropenia Gastroenterology Drug Administration Schedule Esorubicin Internal medicine Humans Medicine Pharmacology (medical) Aged Ovarian Neoplasms Pharmacology Chemotherapy Antibiotics Antineoplastic business.industry Ovarian Neoplasm Middle Aged medicine.disease Surgery Oncology Doxorubicin Vomiting Drug Evaluation Female medicine.symptom business Ovarian cancer |
| Zdroj: | Investigational New Drugs. 8:333-336 |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1007/bf00171850 |
| Popis: | Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink